Literature DB >> 31269273

Functional immune response to influenza H1N1 in children and adults after live attenuated influenza virus vaccination.

Shahinul Islam1,2, Fan Zhou1,2, Sarah Lartey1,2, Kristin G I Mohn1,3, Florian Krammer4, Rebecca Jane Cox1,2,5, Karl Albert Brokstad6.   

Abstract

Influenza virus is a major respiratory pathogen, and vaccination is the main method of prophylaxis. In 2012, the trivalent live attenuated influenza vaccine (LAIV) was licensed in Europe for use in children. Vaccine-induced antibodies directed against the main viral surface glycoproteins, haemagglutinin (HA) and neuraminidase (NA) play important roles in limiting virus infection. The objective of this study was to dissect the influenza-specific antibody responses in children and adults, and T cell responses in children induced after LAIV immunization to the A/H1N1 virus. Blood samples were collected pre- and at 28 and 56 days post-vaccination from 20 children and 20 adults. No increase in micro-neutralization (MN) antibodies against A/H1N1 was observed after vaccination. A/H1N1 stalk-specific neutralizing and NA-inhibiting (NI) antibodies were boosted in children after LAIV. Interferon γ-producing T cells increased significantly in children, and antibody-dependent cellular-mediated cytotoxic (ADCC) cell activity increased slightly in children after vaccination, although this change was not significant. The results indicate that the NI assay is more sensitive to qualitative changes in serum antibodies after LAIV. There was a considerable difference in the immune response in children and adults after vaccination, which may be related to priming and previous influenza history. Our findings warrant further studies for evaluating LAIV vaccination immunogenicity.
© 2019 The Foundation for the Scandinavian Journal of Immunology.

Entities:  

Keywords:  LAIV; adults; children; immune response; influenza A/H1N1

Mesh:

Substances:

Year:  2019        PMID: 31269273      PMCID: PMC6746580          DOI: 10.1111/sji.12801

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  5 in total

1.  Antibody-dependent cell-mediated cytotoxicity antibody responses to inactivated and live-attenuated influenza vaccination in children during 2014-15.

Authors:  Kelsey Florek; James Mutschler; Huong Q McLean; Jennifer P King; Brendan Flannery; Edward A Belongia; Thomas C Friedrich
Journal:  Vaccine       Date:  2019-11-18       Impact factor: 3.641

2.  Talk of the town in 2021: Covid-19 vaccines likely take centre stage.

Authors:  Petter Höglund
Journal:  Scand J Immunol       Date:  2021-01       Impact factor: 3.487

3.  Safety and Immunogenicity of M2-Deficient, Single Replication, Live Influenza Vaccine (M2SR) in Adults.

Authors:  Joseph Eiden; Gilad Gordon; Carlos Fierro; Renee Herber; Roger Aitchison; Robert Belshe; Harry Greenberg; Daniel Hoft; Yasuko Hatta; Michael J Moser; Magdalena Tary-Lehmann; Yoshihiro Kawaoka; Gabriele Neumann; Paul Radspinner; Pamuk Bilsel
Journal:  Vaccines (Basel)       Date:  2021-11-24

4.  Monoclonal Antibody Targeting the HA191/199 Region of H1N1 Influenza Virus Mediates the Damage of Neural Cells.

Authors:  Chun-Yan Guo; Qing Feng; Li-Ting Yan; Xin Xie; Dao-Yan Liang; Yan Li; Yang-Meng Feng; Li-Jun Sun; Jun Hu
Journal:  Biochemistry (Mosc)       Date:  2021-11       Impact factor: 2.487

5.  Matrix M Adjuvanted H5N1 Vaccine Elicits Broadly Neutralizing Antibodies and Neuraminidase Inhibiting Antibodies in Humans That Correlate With In Vivo Protection.

Authors:  Fan Zhou; Lena Hansen; Gabriel Pedersen; Gunnveig Grødeland; Rebecca Cox
Journal:  Front Immunol       Date:  2021-11-23       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.